22-[4-(hexadecyloxy)phenyl]-3,6,9,12,15,18,21-heptaoxadocosan-1-ol | 1004269-56-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 22-[4-(hexadecyloxy)phenyl]-3,6,9,12,15,18,21-heptaoxadocosan-1-ol
• 英文别名: 2-[2-[2-[2-[2-[2-[2-[(4-Hexadecoxyphenyl)methoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
• CAS: 1004269-56-0
• 化学式: C₃₇H₆₈O₉
• 分子量: 656.942
• InChiKey: CDLCQEJKZKVQJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  46
• 可旋转键数：
  38
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  94.1
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-(hexadecyloxy)benzyl alcohol 、 alkaline earth salt of/the/ methylsulfuric acid 在 ytterbium(III) triflate 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 生成 2-[2-[2-[2-[2-[2-[(4-Hexadecoxyphenyl)methoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol 、 22-[4-(hexadecyloxy)phenyl]-3,6,9,12,15,18,21-heptaoxadocosan-1-ol 、
  参考文献：
  名称：

  Novel Amphiphilic Probes for [¹⁸F]-Radiolabeling Preformed Liposomes and Determination of Liposomal Trafficking by Positron Emission Tomography

  摘要：

  Positron-emission tomography (PET) is a noninvasive realtime functional imaging system and is expected to be useful for the development of new drug candidates in clinical trials. For its application with preformulated liposomes, we devised an optimized [F-18]-compound and developed a direct liposome modification method that we termed the "solid-phase transition method". We were successful in using 1-[F-18]fluoro-3,6-dioxatetracosane ([F-18]7a) for in vivo trafficking of liposomes. This method might be a useful tool in preclinical and clinical studies of lipidic particle-related drugs.

  DOI：

  10.1021/jm7010518

文献信息

• Novel Amphiphilic Probes for [¹⁸F]-Radiolabeling Preformed Liposomes and Determination of Liposomal Trafficking by Positron Emission Tomography
  作者：Takeo Urakami、Shuji Akai、Yurie Katayama、Norihiro Harada、Hideo Tsukada、Naoto Oku

  DOI：10.1021/jm7010518

  日期：2007.12.27

  Positron-emission tomography (PET) is a noninvasive realtime functional imaging system and is expected to be useful for the development of new drug candidates in clinical trials. For its application with preformulated liposomes, we devised an optimized [F-18]-compound and developed a direct liposome modification method that we termed the "solid-phase transition method". We were successful in using 1-[F-18]fluoro-3,6-dioxatetracosane ([F-18]7a) for in vivo trafficking of liposomes. This method might be a useful tool in preclinical and clinical studies of lipidic particle-related drugs.